Gene · 6141
RPL18: ribosomal protein L18
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL18: ribosomal protein L18. Genes, record 6141. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6141
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q07020 | Large ribosomal subunit protein eL18 | 188 | 179 | Ensembl, GeneID, HGNC |
Source UniProt
Patents30
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 61996 | Q07020 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 16471 | Q07020 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 8129 | Q07020 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 16471 | Q07020 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 8129 | Q07020 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 73979 | Q07020 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 176950 | Q07020 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9751 | Q07020 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 2118 | Q07020 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 242431 | Q07020 | Espacenet |
1 to 10 of 30
See all 30 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants665
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL18 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 2 | 2025 |
| P20GM121176 | Autophagy, Inflammation and Metabolism (AIM) in Disease Center - Phase 2. | 2 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 2 | 2025 |
| P30CA142543 | UT Southwestern Medical Center Simmons Comprehensive Cancer Center | 2 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 2 | 2025 |
| P50CA116201 | Mayo Clinic Breast Cancer SPORE | 2 | 2025 |
| P50CA196516 | University of Texas Southwestern Medical Center SPORE in Kidney Cancer | 2 | 2025 |
1 to 10 of 665Source NIH's project files
See all 665 nih grantsPapers831
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring Molecular Pathways in Metastasis of Breast Cancer Cells to the Brain: Insights from Gene Expression Analysis and Cellular Origins. | J Microsc Ultrastruct | 2026 | 42824931 | PubTator, text mining | PubMed |
| TRIM21-Mediated ubiquitination of FBL suppresses PI3K/AKT signaling and tumor progression in clear cell renal cell carcinoma. | Cell Mol Life Sci | 2026 | 41863623 | PubTator, text mining | PubMed |
| A three generation family with VACTERL association is found to have a rare form of diamond-blackfan anaemia. | Eur J Hum Genet | 2026 | 41851260 | PubTator, text mining | PubMed |
| Pairing taguchi based design of experiment with response surface methodology for diesel engine performance optimization using biodiesel-magnesium oxide nanoparticles blends. | PLoS One | 2026 | 41779812 | PubTator, text mining | PubMed |
| Manganese modulates hepatocellular carcinoma cytotoxicity and doxorubicin sensitivity in a dose dependent manner. | Front Oncol | 2026 | 41768239 | PubTator, text mining | PubMed |
| Radiomics predicts poorly differentiated hepatocellular carcinoma and uncovers ribosomal-immune dysregulation mechanism. | iScience | 2026 | 41732485 | PubTator, text mining | PubMed |
| Bioreactor expansion of human neural progenitor cells for exosome scalable production and miRNA-engineering. | J Biol Eng | 2026 | 41715202 | PubTator, text mining | PubMed |
| ENY2 transcription and export complex 2 subunit deficiency induces nucleolar stress to inhibit tumor progression through NPM1/MDM2/p53-dependent and -independent responses. | Cell Oncol (Dordr) | 2026 | 41642454 | PubTator, text mining | PubMed |
| Validation of Stable Reference Genes for RT-qPCR Normalization in Oxycetonia jucunda (Coleoptera: Scarabaeidae). | Insects | 2026 | 41598911 | PubTator, text mining | PubMed |
| Exploring molecular signatures in PURA syndrome using muscle proteomics and serum biomarkers. | J Neurol | 2026 | 41575592 | PubTator, text mining | PubMed |
1 to 10 of 831
See all 831 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6141
GET https://conductscience.org/api/genes/v1/6141/patents?page=2